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Background
The ability of mutated cells to give rise to pathological
cancer relies upon the capability of these cells to inter-
act with the immune system and ultimately evade
immune recognition and suppress immune activity
through multiple (differently expressed) mechanisms.
Although our understanding of the tumor-host interac-
tion has dramatically increased in the last ten years,
greatly accelerating the pace of immunotherapy drug
development, a clear need remains for clinical biomar-
kers capable of informing on patient selection, biology-
based combination therapy, and adverse effects monitor-
ing. Due to the highly regulated, multi-step, multi-tissue,
multi-compartmental cancer-immunity cycle, it is unli-
kely that measurements limited to one or few analytes
(e.g., PD-L1) – or even single analyte classes (e.g., DNA,
mRNA, or protein) – will be informative enough for
predictive/prognostic immunotherapy applications. New
developments in multiple biomarker analyte-class optical
barcode counting significantly reduce this problem.
Methods
Recent work from the Weissleder-lab [1] has shown how
optical barcode technology can be utilized for multi-
plexed digital counting of proteins, and be combined
with simultaneous digital counting of nucleic-acids on a
single nCounter analysis system. NanoString has
expanded upon this original work and developed a cancer
immune-profiling technology that simultaneously mea-
sures 770 mRNA’s (unique signatures for 24 infiltrating
immune cell types plus extensive immune-signaling
pathways) plus 30 key immuno-oncology proteins
(including PD-1, PD-L1, PD-L2, CTLA4, OX40) using
small amounts of clinically relevant samples (~ 50,000
PBMCs for mRNA+protein, 1 or 2, 5um slices for mRNA
alone). This technology (“RNA:Protein”) is forming the
basis for multi-year collaborations between NanoString
and both MD Anderson (Houston TX) and the Cancer
Immunotherapy Trials Network (CITN) to discover
unique multi-analyte-type (mRNA + protein) biomarker
signatures to guide cancer immunotherapy.
Results
NanoString gene expression profiling has also been
recently highlighted [2] as a method to select for patients
that will benefit from anti-PD1 based therapy (Keytruda)
in a number of different cancer types. This technology is
also being expanded to work on multi-analyte detection
completely from archival FFPE slices. Several examples of
the utilization of RNA:Protein immune-profiling technol-
ogy to develop biomarker signatures relevant to immuno-
oncology will be presented.
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